2016年至2021年日本制药公司向医疗保健提供商支付的趋势

IF 2.1 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Journal of evaluation in clinical practice Pub Date : 2025-07-17 DOI:10.1111/jep.70169

Keiichiro Hayashi, Akemi Hara, Michioki Endo, Hiroaki Saito, Tetsuya Tanimoto, Akihiko Ozaki

{"title":"2016年至2021年日本制药公司向医疗保健提供商支付的趋势","authors":"Keiichiro Hayashi, Akemi Hara, Michioki Endo, Hiroaki Saito, Tetsuya Tanimoto, Akihiko Ozaki","doi":"10.1111/jep.70169","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Rationale</h3>\n \n <p>Pharmaceutical payments to healthcare providers can pose conflicts of interest. Long-term trends in such payments in Japan remain under explored.</p>\n </section>\n \n <section>\n \n <h3> Aims and Objectives</h3>\n \n <p>This study examined pharmaceutical company payments to healthcare providers in Japan from 2016 to 2021, including the impact of the COVID-19 pandemic.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a repeated cross-sectional analysis using publicly disclosed data on payments (lectures, consulting, and writing) from pharmaceutical companies. Payments were analyzed by year, amount, and specialty.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Total payments remained stable from 2017 to 2019 ($249 million), dropped in 2020 ($172 million), and rose in 2021 ($272 million). The number of recipients declined overall, but mean and median payments per healthcare provider steadily increased. The share receiving over $100,000 rose from 0.09% to 0.17%. Cardiovascular and diabetes/metabolism/endocrinology specialists consistently received the highest payments.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Payments became more concentrated among high-earning physicians following the COVID-19 pandemic. Continued monitoring is needed to manage potential conflicts of interest.</p>\n </section>\n </div>","PeriodicalId":15997,"journal":{"name":"Journal of evaluation in clinical practice","volume":"31 5","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in Pharmaceutical Company Payments to Healthcare Providers in Japan From 2016 to 2021\",\"authors\":\"Keiichiro Hayashi, Akemi Hara, Michioki Endo, Hiroaki Saito, Tetsuya Tanimoto, Akihiko Ozaki\",\"doi\":\"10.1111/jep.70169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Rationale</h3>\\n \\n <p>Pharmaceutical payments to healthcare providers can pose conflicts of interest. Long-term trends in such payments in Japan remain under explored.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims and Objectives</h3>\\n \\n <p>This study examined pharmaceutical company payments to healthcare providers in Japan from 2016 to 2021, including the impact of the COVID-19 pandemic.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted a repeated cross-sectional analysis using publicly disclosed data on payments (lectures, consulting, and writing) from pharmaceutical companies. Payments were analyzed by year, amount, and specialty.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Total payments remained stable from 2017 to 2019 ($249 million), dropped in 2020 ($172 million), and rose in 2021 ($272 million). The number of recipients declined overall, but mean and median payments per healthcare provider steadily increased. The share receiving over $100,000 rose from 0.09% to 0.17%. Cardiovascular and diabetes/metabolism/endocrinology specialists consistently received the highest payments.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Payments became more concentrated among high-earning physicians following the COVID-19 pandemic. Continued monitoring is needed to manage potential conflicts of interest.</p>\\n </section>\\n </div>\",\"PeriodicalId\":15997,\"journal\":{\"name\":\"Journal of evaluation in clinical practice\",\"volume\":\"31 5\",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of evaluation in clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jep.70169\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of evaluation in clinical practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jep.70169","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

向医疗保健提供者支付医药费用可能会造成利益冲突。日本此类支付的长期趋势仍有待研究。本研究调查了2016年至2021年日本制药公司向医疗保健提供者支付的费用，包括COVID-19大流行的影响。方法：我们使用制药公司公开披露的付款（讲座、咨询和写作）数据进行了重复的横断面分析。付款按年份、金额和专业进行分析。从2017年到2019年，支付总额保持稳定（2.49亿美元），到2020年下降（1.72亿美元），到2021年上升（2.72亿美元）。受助人的数量总体下降，但每个医疗保健提供者的平均和中位数支付稳步增加。收入超过10万美元的比例从0.09%上升到0.17%。心血管和糖尿病/代谢/内分泌专家一直获得最高的报酬。结论2019冠状病毒病大流行后，薪酬向高收入医生集中。需要继续进行监测，以管理潜在的利益冲突。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Trends in Pharmaceutical Company Payments to Healthcare Providers in Japan From 2016 to 2021

Rationale

Pharmaceutical payments to healthcare providers can pose conflicts of interest. Long-term trends in such payments in Japan remain under explored.

Aims and Objectives

This study examined pharmaceutical company payments to healthcare providers in Japan from 2016 to 2021, including the impact of the COVID-19 pandemic.

Methods

We conducted a repeated cross-sectional analysis using publicly disclosed data on payments (lectures, consulting, and writing) from pharmaceutical companies. Payments were analyzed by year, amount, and specialty.

Results

Total payments remained stable from 2017 to 2019 ($249 million), dropped in 2020 ($172 million), and rose in 2021 ($272 million). The number of recipients declined overall, but mean and median payments per healthcare provider steadily increased. The share receiving over $100,000 rose from 0.09% to 0.17%. Cardiovascular and diabetes/metabolism/endocrinology specialists consistently received the highest payments.

Conclusion

Payments became more concentrated among high-earning physicians following the COVID-19 pandemic. Continued monitoring is needed to manage potential conflicts of interest.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of evaluation in clinical practice 医学-卫生保健

CiteScore

4.80

自引率

4.20%

发文量

143

审稿时长

3-8 weeks

期刊介绍： The Journal of Evaluation in Clinical Practice aims to promote the evaluation and development of clinical practice across medicine, nursing and the allied health professions. All aspects of health services research and public health policy analysis and debate are of interest to the Journal whether studied from a population-based or individual patient-centred perspective. Of particular interest to the Journal are submissions on all aspects of clinical effectiveness and efficiency including evidence-based medicine, clinical practice guidelines, clinical decision making, clinical services organisation, implementation and delivery, health economic evaluation, health process and outcome measurement and new or improved methods (conceptual and statistical) for systematic inquiry into clinical practice. Papers may take a classical quantitative or qualitative approach to investigation (or may utilise both techniques) or may take the form of learned essays, structured/systematic reviews and critiques.